Previous 10 | Next 10 |
2023-05-04 17:31:44 ET Crinetics Pharmaceuticals press release ( NASDAQ: CRNX ): Q1 GAAP EPS of -$0.85 misses by $0.01 . Revenue of $2.67M (-14.7% Y/Y) beats by $2.43M . For further details see: Crinetics Pharmaceuticals GAAP EPS of -$0.85 misses by $0.01...
Phase 3 PATHFNDR-1 study topline data expected in 3Q 2023 Phase 3 PATHFNDR-2 study topline data expected in 1Q 2024 and enrollment target increased to up to 98 per prespecified protocol criteria Paltusotine’s Phase 2 study in carcinoid syndrome on track for preliminary da...
2023-03-06 10:13:25 ET Summary Crinetics Pharmaceuticals develops therapeutics for endocrine diseases and tumors. Its lead drug candidate, paltusotine, is undergoing two Phase 3 trials for acromegaly treatment. In acromegaly, the excessive production of growth hormone and insulin-...
Crinetics Pharmaceuticals press release ( NASDAQ: CRNX ): Q4 GAAP EPS of -$0.84 misses by $0.01 . Revenue of $0.71M (-34.3% Y/Y) beats by $0.41M . Unrestricted cash, cash equivalents, and investments totaled $334.4 million as of December 31, 2022, compared to $368.4 mi...
Paltusotine’s Phase 3 PATHFNDR-1 study enrollment complete and topline data expected in 3Q 2023 Paltusotine’s Phase 3 PATHFNDR-2 study enrollment ongoing with topline data now expected in 1Q 2024 Pending a successful outcome from the PATHFNDR studies, an NDA ...
SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will participate in a fireside chat at the annual SVB Securities Global Biopharma Conference, which is being held in a virtual format February 14-16, 2023. Detai...
Efforts to further increase commercial readiness ongoing as Phase 3 PATHFNDR trials of paltusotine in acromegaly approach topline data readouts which are expected in 2H 2023 Phase 2 trial of paltusotine in carcinoid syndrome on track for topline data in 2H 2023 Clinical trials o...
Summary Acromegaly pipeline continues to advance with two Phase 3 readouts scheduled for 2023. FDA's red-light of the CRN04777 Phase 2 study received muted price response. Technicals unsupportive of re-rating for now, hence 2023 will be key year for CRNX. Net-net, we rate CRNX a...
SAN DIEGO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today provided an update on its development program for CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist being developed as a treatment for congenital hyperinsulinis...
SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 5 th Annual Evercore ISI HealthCONx Conference being held virtually November 29 &...
News, Short Squeeze, Breakout and More Instantly...
Crinetics Pharmaceuticals Inc. Company Name:
CRNX Stock Symbol:
NASDAQ Market:
Crinetics Pharmaceuticals Inc. Website:
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET that day to...
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 137,900 shares of its com...
2024-06-25 22:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...